Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | PLEC | Q15149 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919905 | 1.00 | POLB (0.51) | POLBALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL2876296 | 0.87 | ALOX15 (0.58) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL2876298 | 0.87 | ALOX15 (0.58) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL2078912 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL918950 | 0.86 | KMT2A (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL3756341 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL3756338 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL2078910 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL918951 | 0.86 | KMT2A (0.50) | ALDH1A1KDM4EL3MBTL1MAPTPKM | |
| SCHEMBL11749888 | 0.86 | CA2 (0.61) | ALDH1A1KDM4EL3MBTL1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1896459-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137797-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | POLB 4402/4885ALDH1A1 856/4885KDM4E 1118/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | POLB 1197/4885ALDH1A1 468/4885KDM4E 1375/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | POLB 1197/4885ALDH1A1 468/4885KDM4E 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.